KALV Stock Overview
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
KalVista Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.74 |
| 52 Week High | US$16.88 |
| 52 Week Low | US$7.21 |
| Beta | 0.91 |
| 1 Month Change | -1.59% |
| 3 Month Change | -8.50% |
| 1 Year Change | 45.66% |
| 3 Year Change | -49.22% |
| 5 Year Change | -55.53% |
| Change since IPO | 40.10% |
Recent News & Updates
Recent updates
KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Feb 14We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Jan 30
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Oct 04We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
May 02KalVista: Another Setback But The Key Value Driver Is Still In Place
Oct 14Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
Sep 24KalVista Pharmaceticals GAAP EPS of -$0.94
Sep 08KalVista reaches five-month high as rival tumbles on hereditary angioedema
Aug 22KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11
Jul 07Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
May 18Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth
Feb 02We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed
Sep 24We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely
Jul 02KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study
Jun 07KalVista Pharmaceuticals names new medical chief
May 03How Much Did KalVista Pharmaceuticals' (NASDAQ:KALV) CEO Pocket Last Year?
Mar 01Estimating The Fair Value Of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Feb 03
Shareholder Returns
| KALV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.3% | -2.8% | -1.7% |
| 1Y | 45.7% | -0.2% | 22.4% |
Return vs Industry: KALV exceeded the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: KALV exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| KALV volatility | |
|---|---|
| KALV Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KALV's share price has been volatile over the past 3 months.
Volatility Over Time: KALV's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 118 | Ben Palleiko | www.kalvista.com |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE.
KalVista Pharmaceuticals, Inc. Fundamentals Summary
| KALV fundamental statistics | |
|---|---|
| Market cap | US$501.62m |
| Earnings (TTM) | -US$108.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.6x
P/E RatioIs KALV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KALV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$84.87m |
| Gross Profit | -US$84.87m |
| Other Expenses | US$23.43m |
| Earnings | -US$108.30m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KALV perform over the long term?
See historical performance and comparison